FAQs & How to use this site
Home | About Us | Contact Us
The Front Line
The Front Line: Charles D. Blanke, MD, SWOG Chair

PREVIOUS POSTS November 2017

October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013


Apr 11, 2014 - SWOG's leadership team has been working behind the scenes to cultivate new relationships with a wide range of partners -- with foundations and professional societies, as you might expect, and with some unexpected allies as well, such as organizations with a stake in health informatics. We are trying to connect SWOG more broadly in part because we have learned much from the successful public-private partnership underlying our Lung Master Protocol, and because the National Cancer Institute has encouraged collaboration with non-Network groups. Increasingly, we recognize that such partnerships are becoming vital to thriving in an era of ever more complex clinical trials, particularly involving rare cancers or even small subsets of common cancers.

Some of these partnerships truly are highly public -- for example working, along with the NCI, with Friends of Cancer Research, the Foundation for the National Institutes of Health, and a group of industry associates to launch the Lung Master Protocol, now rapidly approaching activation and discussed above. Others are quieter but no less essential, such as our partnership with Livestrong, which has contributed significantly to our developing effective strategies in the area of adolescent and young adult cancer.

Still other partnerships are in gestation. We are in advanced planning stages with a VA consortium featured in previous columns. I and other members of the leadership team have held a number of meetings with potential business partners who can also help with data-organized research. We will continue to discuss and brainstorm how we might collaborate synergistically in the latter setting, to the benefit of everyone. This might range from establishing more formalized modes of interaction, to co-developing education and training modules, to proposing large-scale joint research projects, with a patient-centered emphasis.

SWOG will continue to evolve, as you all desire and as our environment requires. We will continue to design and conduct cancer clinical research in the public interest, working with anyone who shares our highest goal -- improved outcomes for patients.


SWOG Logo Disclaimer | Copyright ©1999-2017 SWOG. All rights reserved.
Design and Hosting by nuMedia
SWOG is FISMA CertifiedSWOG is FISMA Certified